Resilience Logic Highlights, Innovative Drugs Sector Expected to Strengthen,E Fund Biomedicine ETF(03186.HK) Rises 2.95% Intraday

NewTimeSpace News: Since 2025, boosted by strong overseas expansion and fading policy disturbances, the innovative drugs sector has seen a clear recovery in ROE (TTM). As of 13:30 on April 15, 2026, E Fund Biomedicine ETF(03186.HK) rose 2.95% to HK$16.76.

E Fund Biomedicine ETF(03186.HK) tracks the Solactive Select Biomedicine Index. Its constituents are mainly focused on innovative drugs, covering cutting-edge sectors such as weight loss & metabolism, oncology, and autoimmunity.

In terms of news, the easing of the US-Iran conflict has recently triggered a rebound in the pharmaceutical and biomedical sector. The innovative drug industrial chain, which had fallen sharply earlier, led the rebound and drove the sector higher.

BOCIC stated that if the Israel-US-Iran conflict eases, overseas markets are expected to continue the interest rate cut cycle, and the 10-year US Treasury yield may hit an inflection point, which is positive for investments in the innovative drugs sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.